Analysts’ Recent Ratings Changes for Climb Bio (CLYM)

Climb Bio (NASDAQ: CLYM) has recently received a number of price target changes and ratings updates:

• 9/4/2026 – Climb Bio had its “buy” rating reaffirmed by B Riley.
• 9/3/2026 – Climb Bio was given a new $40.00 price target by Piper Sandler. They now have an “overweight” rating on the stock.
• 9/3/2026 – Climb Bio had its price target raised by Robert W. Baird from $21.00 to $25.00. They now have an “outperform” rating on the stock.
• 9/3/2026 – Climb Bio had its price target raised by BTIG Research from $20.00 to $32.00. They now have a “buy” rating on the stock.
• 8/24/2026 – Climb Bio had its price target raised by HC Wainwright from $20.00 to $24.00. They now have a “buy” rating on the stock.
• 8/19/2026 – Climb Bio had its “outperform” rating reaffirmed by Wedbush. They now have a $20.00 price target on the stock.
• 8/7/2026 – Climb Bio had its price target raised by Truist Financial Corporation from $17.00 to $25.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Climb Bio is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $23.00 price target on the stock.
• 8/3/2026 – Climb Bio is now covered by Royal Bank Of Canada. They set a “moderate buy” rating and a $23.00 price target on the stock.
• 7/27/2026 – Climb Bio had its price target raised by Wedbush from $17.00 to $20.00. They now have an “outperform” rating on the stock.
• 7/17/2026 – Climb Bio had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.